Exploring new treatments for aggressive brain tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on glioblastoma and glioma, investigating the role of cancer stem cells (CSCs) in tumor aggressiveness and resistance to current therapies. It aims to understand how the hypoxic tumor microenvironment influences CSC behavior and their response to treatment. By isolating cells from tumor biopsies and examining biomarkers, the study seeks to uncover potential therapeutic targets related to sphingolipids and their metabolic pathways. The findings could lead to more effective treatment strategies for patients with these challenging brain tumors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with glioma diagnosed histologically confirmed (WHO) undergoing surgical resection;
* hypomethylation or hypermethylation of MGMT assessed post-surgery for patients affected by GBM;
* adult patients (≥18 years), both sexes;
* Patients undergoing Stupp protocol including patients aged \> 70 years performing the hypofractionated protocol and three weeks of chemotherapy;
* Karnofsky Performance Status (KPS)\> 60 assessed post-surgery;
* freely given written informed consent prior to any activity related to the study. erine

Exclusion Criteria:

* patients who do not sign the informed consent

Where it's running

• Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
  Milan, Italy Recruiting

Study contacts

• Principal investigator: Stefania E Navone, PhD — Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
• Study coordinator: Stefania E Navone, PhD
• Email: stefania.navone@policlinico.mi.it
• Phone: 0255034268

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• YN003 injection in glioma patients

  This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.

  Recruiting at 2 sites Phase 1 Beijing Inno Medicine Co., Ltd. · Los Angeles, California and 4 other locations · NCT07929909

• Brain connectome project in adults with brain glioma undergoing surgery

  This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.

  Recruiting Northwell Health · New York, New York · NCT07927595

• Sitagliptin plus bevacizumab for recurrent grade 4 glioma

  This study tests whether adding sitagliptin to bevacizumab can help people whose recurrent glioblastoma or other grade 4 gliomas respond to treatment and to find a safe dose when used with bevacizumab.

  Recruiting Phase 1 University of Iowa · Iowa City, Iowa · NCT07541781

• Phase 1 safety and dose-finding of GLIX1 for adults with recurrent or progressive high-grade glioma

  This trial will test whether taking oral GLIX1 daily is safe, tolerable, and shows early anti-tumor activity in adults with recurrent or progressive high-grade glioma.

  Recruiting at 4 sites Phase 1 Tetragon Biosciences Ltd · Palo Alto, California and 3 other locations · NCT07464925

• Skin closure after brain tumor surgery: running absorbable versus interrupted non-absorbable sutures

  This will test whether absorbable running intradermal sutures or non-absorbable interrupted transdermal sutures produce better wound healing after craniotomy in adults with supratentorial brain tumors.

  Recruiting Medical University of Warsaw · Warsaw, Masovian Voivodeship · NCT07413796

• Cerebrospinal fluid leak after brain tumor surgery

  This project will look at adults having planned supratentorial craniotomy for intracranial tumors to see how often cerebrospinal fluid leaks occur and what complications they cause.

  Recruiting Medical University of Warsaw · Warsaw · NCT07411690

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.